Alnylam Pharmaceuticals logo

Associate Director, Records Management

Alnylam Pharmaceuticals

Cambridge, MAHybridPosted 1 day ago$170,000 - $230,000 USD
Full TimeDirector & AboveCorporate FunctionsPharmaceutical
Original posting ↗

Summary

Alnylam is seeking an Associate Director, Records Management to build and lead a best-in-class enterprise Records Management function. This is a highly visible, high impact role for an experienced Records Manager who is energized by the opportunity to shape how a global commercial-stage, large cap biopharmaceutical company builds a compliant and consistent approach to managing records.

Job description

Overview

Alnylam is seeking an Associate Director, Records Management to build and lead a best-in-class enterprise Records Management function. This is a highly visible, high impact role for an experienced Records Manager who is energized by the opportunity to shape how a global commercial-stage, large cap biopharmaceutical company builds a compliant and consistent approach to managing records.

Reporting to the VP, Legal Operations, this leader will provide centralized coordination across legal, business, and technology teams to operationalize retention, legal hold, and defensible disposition activities throughout the data lifecycle. This individual will define what qualifies as a record and establish classification requirements, ensure the appropriate retention requirements are applied, guide the appropriate use and handling of records, monitor policy compliance, and enforce legal holds and dispositions when needed.

This is a hybrid role and will be primarily based in Cambridge, MA.

Responsibilities

  • Own the records management program, including the enterprise policy, and act as a central point of knowledge for the records management policy.
  • Own operationalization of retention schedules and manage oversight and accountability.
  • Define and track KPIs and metrics for reporting to various stakeholders across the enterprise.
  • Enforce legal hold obligations.
  • Oversee exception management and escalation for non-compliance or deviations from retention policies.
  • Make decisions about retention and disposal escalations/exceptions that are not regulatory in nature.
  • Partner with IT to select and implement enabling technology, automation, and control mechanisms.
  • Partner with functional-specific record owners to support their needs; facilitate periodic attestations for business managed records.

Qualifications

  • 5-8 years of experience leading a record management function, preferably in a life sciences, healthcare, or other highly regulated organization.
  • Ability to interpret applicable legal, regulatory and compliance requirements.
  • Ability to execute at scale by guiding record stewards, standardizing practices and partnering with technology teams to embed records management requirements into core systems.
  • Exercise judgment on exceptions and defensible decisions.
  • Participating member in PRIMO (Pharmaceutical Records & Information Management Organization) highly desired.

Requirements

  • 5-8 years of experience leading a record management function
  • Preferably in a life sciences, healthcare, or other highly regulated organization
  • Ability to interpret applicable legal, regulatory and compliance requirements
  • Ability to execute at scale by guiding record stewards, standardizing practices and partnering with technology teams
  • Exercise judgment on exceptions and defensible decisions
  • Participating member in PRIMO highly desired

Benefits

  • Medical, Dental & Vision
  • Life & Disability Insurance
  • Lifestyle Reimbursement Program
  • Flexible Spending Account
  • Health Savings Account
  • 401(k) Matching
  • Paid Time Off
  • Wellness Days
  • Holidays
  • Company Recharge Breaks
  • Family Resources
  • Leave

Company overview

Alnylam Pharmaceuticals is a pioneering American biopharmaceutical company and the global leader in RNA interference (RNAi) therapeutics. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam has revolutionized the field of genetic medicine by developing innovative treatments that 'silence' disease-causing genes. The company achieved a historic milestone in 2018 with the approval of Onpattro (patisiran), the world's first RNAi therapeutic, which treats hereditary transthyretin-mediated amyloidosis. Since then, Alnylam has successfully commercialized five additional RNAi medicines targeting rare genetic disorders including acute hepatic porphyria, primary hyperoxaluria type 1, and transthyretin amyloidosis. With over 2,100 employees worldwide, Alnylam maintains a robust pipeline of investigational therapies across genetic medicines, cardiometabolic diseases, and hepatic infectious diseases. The company's groundbreaking work has established RNAi as a clinically validated therapeutic platform, earning recognition as one of the most innovative biopharmaceutical companies and consistently ranking as a top employer in the life sciences industry.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.